Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GGT1 | P19440 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282326 | 1.00 | KMT2A (0.31) | KMT2AGGT1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL6064423 | 0.85 | — | — | |
| SCHEMBL23576186 | 0.83 | NAALAD2 (0.45) | KMT2AMEN1ALDH1A1CYP1A2THRB | |
| SCHEMBL3180159 | 0.82 | GGT1 (0.31) | KMT2AGGT1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL27752979 | 0.82 | GGT1 (0.31) | KMT2AGGT1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL5716372 | 0.82 | GGT1 (0.34) | KMT2AGGT1MEN1ALDH1A1CYP1A2 | |
| SCHEMBL31026562 | 0.81 | ALDH1A1 (0.38) | ALDH1A1NAALAD2 | |
| SCHEMBL27396655 | 0.81 | SOAT1 (0.46) | KMT2AMEN1ALDH1A1CYP1A2ALOX15 | |
| Octadecanoic Acid Amide SCHEMBL28012042 | 0.81 | SOAT1 (0.46) | KMT2AMEN1ALDH1A1CYP1A2ALOX15 | |
| SCHEMBL1281745 | 0.78 | TSHR (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| CN-110869544-A | Cyclic peptide compound having high membrane permeability and library containing same | 中外制药株式会社 | 2020-03-06 | — | — | CN | disclosed |
| US-9005920-B2 | Solution for cell-free protein synthesis, kit for cell-free protein synthesis, and method of protein synthesis | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2447365-A1 | CELL-FREE PROTEIN SYNTHESIS SOLUTION, CELL-FREE PROTEIN SYNTHESIS KIT, AND PROTEIN SYNTHESIS METHOD | Toyota Jidosha Kabushiki Kaisha (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20120088269-A1 | SOLUTION FOR CELL-FREE PROTEIN SYNTHESIS, KIT FOR CELL-FREE PROTEIN SYNTHESIS, AND METHOD OF PROTEIN SYNTHESIS | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088269-A1 | SOLUTION FOR CELL-FREE PROTEIN SYNTHESIS, KIT FOR CELL-FREE PROTEIN SYNTHESIS, AND METHOD OF PROTEIN SYNTHESIS | SMS, RNMT, SET | KMT2A 651/4885GGT1 722/4885MEN1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.